Cerity Partners LLC Makes New $36,000 Investment in OPKO Health, Inc. (NASDAQ:OPK)

Cerity Partners LLC purchased a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,528 shares of the biotechnology company’s stock, valued at approximately $36,000.

A number of other institutional investors and hedge funds have also made changes to their positions in OPK. Capital Advisors Inc. OK increased its stake in shares of OPKO Health by 133.3% during the first quarter. Capital Advisors Inc. OK now owns 350,000 shares of the biotechnology company’s stock worth $581,000 after buying an additional 200,000 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of OPKO Health during the first quarter worth approximately $139,000. PFG Investments LLC increased its stake in shares of OPKO Health by 4.9% during the first quarter. PFG Investments LLC now owns 1,217,360 shares of the biotechnology company’s stock worth $2,021,000 after buying an additional 56,475 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of OPKO Health by 158.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 74,706 shares of the biotechnology company’s stock worth $124,000 after buying an additional 45,798 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of OPKO Health by 9.1% during the first quarter. Assenagon Asset Management S.A. now owns 935,100 shares of the biotechnology company’s stock worth $1,563,000 after buying an additional 78,362 shares during the period. 64.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on OPK shares. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. JPMorgan Chase & Co. started coverage on OPKO Health in a report on Friday, April 25th. They issued a “neutral” rating for the company. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $2.75.

OPKO Health Price Performance

OPK stock opened at $1.34 on Thursday. The company has a market capitalization of $1.06 billion, a P/E ratio of -19.14 and a beta of 1.34. OPKO Health, Inc. has a twelve month low of $1.21 and a twelve month high of $2.04. The business has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.48. The company has a current ratio of 2.49, a quick ratio of 2.28 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. OPKO Health’s revenue was down 13.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.12) earnings per share. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.